Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.
Frequently asked questions
What sector does TVGN (TVGN) operate in?
TVGN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is TVGN (TVGN) current stock price?
As of the latest data, TVGN stock price is $6.25, with a previous close of $6.53. TVGN lost -$0.28 in the last trading session, representing a -4.29% loss.
What is TVGN (TVGN) current market capitalization?
TVGN market cap is approximately 40.70 million.
What is TVGN (TVGN) Earnings Per Share (EPS)?
The trailing EPS is -$6.29, and the forward EPS is -$10.00.
What is TVGN (TVGN) EBITDA?
TVGN EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -5.60 million.
Does TVGN (TVGN) pay dividends?
No. TVGN does not pay a dividend.
What is TVGN (TVGN) beta (volatility) score?
TVGN has a beta of 0.192, indicating lower volatility than the overall market.
